# Safest Choice of Antihypertensive Regimen for Postpartum Hypertension

Study · id `cardio:ct-nct05551104` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05551104](<https://clinicaltrials.gov/study/NCT05551104>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05551104

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.

## Technical summary

Registry record NCT05551104. Randomized; no masking; primary purpose treatment. Start 2023-05-08 (actual); primary completion 2027-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT05551104, source copy `cardio:ctgov-nct05551104-2026-02-04`, retrieved 2026-10-26)
- Started: 2023-05-08 (actual) (ClinicalTrials.gov record NCT05551104, source copy `cardio:ctgov-nct05551104-2026-02-04`, retrieved 2026-10-26)
- Primary completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT05551104, source copy `cardio:ctgov-nct05551104-2026-02-04`, retrieved 2026-10-26)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT05551104, source copy `cardio:ctgov-nct05551104-2026-02-04`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05551104, source copy `cardio:ctgov-nct05551104-2026-02-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05551104-2026-02-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safest Choice of Antihypertensive Regimen for Postpartum Hypertension
- Acronym: SCARPH
- Condition: Postpartum Complication
- Condition: Maternal Hypertension
- Condition: High Blood Pressure
- Intervention (Drug): Oral Nifedipine
- Intervention (Drug): Oral Labetalol
- Lead sponsor: Loma Linda University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 752efe1dad4515ea4547ea9a6686d58ff306871bdba349fa5b14d39aab566f0f
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
